# Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

> **NCT00536172** · PHASE4 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 160 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Escitalopram
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00536172
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-01
- **Primary completion:** 2012-06-01
- **Final completion:** 2012-06-01
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536172, "Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00536172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*